Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
BioNTech (NASDAQ:BNTX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $113.00 price target on the stock.
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline [Yahoo! Finance]
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer